Icon

TYKERB (nda022059)- (EQ 250MG BASE)

LAPATINIB DITOSYLATE NOVARTIS
EQ 250MG BASE
Yes No
2029-Sep-18 2012-Mar-13
None None
None No
TYKERB is a kinase inhibitor indicated in combination with: • capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. • letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
1 0 1
Total Other Developers 1
Drugs with Suitability No
EQ 250MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 1
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** ***** ****** ******* *********** ****** ********, ******, **********, ********* *** ***, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** **.: ** & **, ****, ***** ****** ****, ********, *************, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.